DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

Overview

This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis

Full Title of Study: “DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2, 2021

Interventions

  • Drug: Dexamethasone ophthalmic insert 0.4Mg
    • Dextenza 0.4Mg Ophthalmic Insert
  • Drug: 0.2% loteprednol etabonate ophthalmic suspension
    • 0.2% loteprednol etabonate ophthalmic suspension
  • Drug: olopatadine hydrochloride ophthalmic solution 0.7%
    • olopatadine hydrochloride ophthalmic solution 0.7%

Arms, Groups and Cohorts

  • Experimental: DEXTENZA
    • DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
  • Active Comparator: Antihistamine
    • PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% for topical ophthalmic administration.
  • Active Comparator: Topical Steroid
    • ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.

Clinical Trial Outcome Measures

Primary Measures

  • Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at Day 30 (final visit)
    • Time Frame: 30 days
    • Patient-reported treatment preference of self-administered topical therapy versus physician-administered therapy at Day 30 (final visit)

Participating in This Clinical Trial

Inclusion Criteria

  • Be at least 18 years of age – Provide written informed consent and sign HIPAA form – Be willing and able to follow all instructions and attend all study visits – Be able and willing to discontinue wearing contact lenses throughout the study period – Have a BCVA of ≥50 ETDRS letters (20/100 Snellen equivalent or better) in each eye as measured at Screening visit – Have urine pregnancy testing for women considered capable of becoming pregnant; not be lactating; and agree to use a medically acceptable form of birth control throughout the study period – Have a positive history of bilateral ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen as confirmed by the allergy testing at the Screening visit Exclusion Criteria:

  • • Known contraindications or sensitivities to the use of any of the medications required per protocol, including known steroid responders – Have any ocular condition that in the opinion of the Investigator could affect the subject's safety or study parameters (including, but not limited to uncontrolled narrow angle glaucoma, severe blepharitis, follicular conjunctivitis, iritis, pterygium, dry eye diagnosis, or active ocular infection) – Have a known history of retinal detachment, diabetic retinopathy, or active retinal disease – Use of systemic, inhaled, or nasal steroids – Use of new systemic antihistamine use within 30 days of Screening visit – Use of ocular or topical non-steroidal anti-inflammatory drugs (NSAIDs) – Use of lid scrubs – Use of decongestants – Use of immunotherapeutic agents – Use of monoamine oxidase inhibitors (MAOIs) – Have a congenital or ocular anomaly or anomaly of the punctum that may preclude placement of DEXTENZA

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Clinical Research Center of Florida
  • Collaborator
    • Ocular Therapeutix, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.